January 9, 2025
Oxford Cancer Analytics (OXcan), the medtech company developing blood tests for early cancer detection using advanced proteomics and AI, today announced it has raised US$11 million in Series A funding from global investors, including in-field institutional investors in disease detection and diagnostics. With the close of this round, Dr. Heinrich Roder, expert in lung cancer proteomics liquid biopsy, was appointed as Senior Vice President of Research and Development at OXcan.
Read the full article
9.28.2021
Can we beat lung cancer? OXcan, can. Every day in the UK, around 130 people are diagnosed with lung cancer. If you’re diagnosed during its earliest stage, you have a 57% chance of living for more than five years. If you’re diagnosed during its latest stage, your chances of survival are reduced to just 3%. That’s why lung cancer is the deadliest cancer anyone can face. Fortunately, OXcan is striving to identify more cases, earlier.
Read more
7.15.2021
Imagine the day when all cancers can be cured - it’s the ultimate objective of cancer research. Yet according to the World Health Organisation, cancer accounted for nearly 10 million deaths, globally, in 2020 alone.
Read more
11.23.2020
KQ Labs, an accelerator programme focused on data-driven health, run by the Francis Crick Institute and now funded by LifeArc, has selected ten new start-ups for its third cohort.
Read more
3.15.2019
The overall winner of the £10,000 prize for the best idea in the All-Innovate contest was DECancer.AI, developed by a team from Jesus College. Their personalised diagnostic platform uses AI to detect early cancer through analysis of an affordable blood test, combined with personalised medical history of the patient, allowing early treatment and cure.
Read more
For press enquiries, interviews and requests to re-use content, please contact us
%20(1).svg)
